Epidemiological data positively correlate plasma serum amyloid A (SAA) levels with cardiovascular disease severity and mortality. Studies by several investigators have indicated a causal role for SAA in the development of atherosclerosis in animal models. Suppression of SAA attenuates the development of angiotensin II (AngII)-induced abdominal aortic aneurysm (AAA) formation in mice. Thus, SAA is not just a marker for cardiovascular disease (CVD) development, but it is a key player. However, to consider SAA as a therapeutic target for these diseases, the pathway leading to its involvement needs to be understood. This review provides a brief description of the pathobiological significance of this enigmatic molecule. The purpose of this review is to summarize the data relevant to its role in the development of CVD, the pitfalls in SAA research, and unanswered questions in the field.
Digital Object Identifier (DOI)
This work was supported in part by funding from the National Institutes of Health R01 HL147381 and the Department of Veterans Affairs BX004275.
Shridas, Preetha; Patrick, Avery C.; and Tannock, Lisa R., "Role of Serum Amyloid A in Abdominal Aortic Aneurysm and Related Cardiovascular Diseases" (2021). Internal Medicine Faculty Publications. 276.